Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GABO:mi Resource Report Resource Website |
GABO:mi (RRID:SCR_003956) | GABO:mi | commercial organization | THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021. Small and medium-sized enterprise (SME) that is expert in management of research projects. Initially, they provide support with help and advice when applying for European research grants - free of charge. From project start, they take over contract negotiations, financial management, reporting to the EC, meeting organization, public relations and much more. ARTTIC Innovation GmbH took over GAVBO:mi. | project management |
is related to: OncoTrack is related to: European Lead Factory is related to: EU-AIMS is related to: NEWMEDS is related to: ARTTIC Innovation GmbH |
grid.10404.31, ISNI: 0000 0004 0377 0748, nlx_158356 | https://ror.org/00a99v816 | SCR_003956 | GABO:mi Gesellschaft f??r Ablauforganisation :milliarium mbH & Co. KG, GABO MI Society for workflow management, GABO:mi Gesellschaft fur Ablauforganisation:milliarium mbH & Co. KG, GABO:mi Gesellschaft f??r Ablauforganisation:milliarium mbH & Co KG, GABO:mi Society for workflow management, GABO:mi Gesellschaft f??r Ablauforganisation:milliarium mbH & Co. KG, GABO:milliarium, GABO:mi Gesellschaft fur Ablauforganisation :milliarium mbH & Co. KG | 2026-09-12 12:56:05 | 0 | |||||||
|
Interface Europe Resource Report Resource Website |
Interface Europe (RRID:SCR_003955) | IE | commercial organization | THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021.Commercial organization with expertise in European research and innovation that provide both science providers (researchers) and technology users (Industry including SMEs, public authorities, Universities, clusters, etc.) tailor-made services to give the highest possible European added value to their project. | European research and innovation |
is related to: MIP-DILI is parent organization of: MIP-DILI |
nlx_158364 | SCR_003955 | 2026-09-12 12:56:05 | 0 | |||||||||
|
Experimental Pharmacology and Oncology Berlin-Buch Resource Report Resource Website 1+ mentions |
Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954) | EPO | commercial organization | A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth. | tumor model, pharmaceutical, oncology, in vitro, in vivo, antitumor, preclinical, pharmacology, pharmacokinetics, toxicology, anticancer, therapeutic, biomarker, imaging, testing, validation, target | is related to: OncoTrack | Tumor, Cancer | nlx_158355 | SCR_003954 | EPO - Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology Berlin-Buch, Experimental Pharmacology & Oncology Berlin-Buch GmbH, EPO Berlin-Buch GmbH, EPO-GmbH | 2026-09-12 12:56:05 | 2 | |||||||
|
Alacris Theranostics Resource Report Resource Website |
Alacris Theranostics (RRID:SCR_003953) | Alacris | commercial organization | Commercial organization that uses next generation sequencing technologies coupled with computational modeling of tumor and somatic tissues in order to identify individualized therapies for cancer patients. The company also uses these technologies to help pharmaceutical partners stratify patients for their clinical trials. Alacris has an exclusive worldwide commercial license for the computational modeling of tumors and somatic tissues using proprietary computational systems modeling technologies ModCell developed at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin coupled with next generation sequencing and genotyping technology developed at Harvard Medical School in Boston. The company also is building up the first next generation sequencing center in Europe for clinical operations. | next generation sequencing, computational modeling, clinical trial, somatic tissue, genotyping, genomics, oncogenomics, diagnostics, therapy, disease model, drug, personalized medicine, biomarker, drug development, tumor model, analysis, oncology | is related to: OncoTrack | Tumor, Cancer | nlx_158354, grid.473915.d | https://ror.org/04a0gnr15 | SCR_003953 | Alacris Theranostics GmbH | 2026-09-12 12:56:05 | 0 | ||||||
|
Psynova Neurotech Resource Report Resource Website 1+ mentions |
Psynova Neurotech (RRID:SCR_003959) | Psynova | commercial organization | Commercial organization focused on the development and exploitation of novel biomarkers for psychiatric illnesses. They provide industrial and academic partners with comprehensive biomarker discovery services in commercial and collaborative projects. They operate in the field of psychiatric disorders and their products and services are designed to excel biomarker research. In 2010, Psynova Neurotech and its partner company Rules-Based-Medicine Inc (now MyriadRBM) conducted a beta launch of a blood test aiding in the diagnosis of schizophrenia (http://www.veripsych.com/). They are now refining the test and have shifted their focus to the development of new blood-based biomarker tests that aid in the diagnosis, prognosis and differential diagnosis of schizophrenia, bipolar disorder and major depression. They offer not only their pre-selceted Multiple Reaction Monitoring (MRM) and Multiplex Immunoassay products, but also custom build panels. If they are provided with a list of analyses to evaluate, they can produce an analytical panel according to individual needs utilizing either MRM or Multiplex Immunoassay technologies., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biomarker, neuropsychiatry, preclinical, model, diagnosis, blood, drug response, immunoassay, brain tissue, mass spectrometry, analysis |
is related to: University of Cambridge; Cambridge; United Kingdom is related to: NEWMEDS |
Schizophrenia, Psychiatric disorder, Bipolar Disorder, Major Depressive Disorder | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158360 | SCR_003959 | Psynova Neurotech Ltd | 2026-09-12 12:56:06 | 9 | ||||||
|
Coordinating center for infectious diseases Resource Report Resource Website |
Coordinating center for infectious diseases (RRID:SCR_003958) | CCID, CH | government granting agency | http://www.thecommunityguide.org/uses/funding.html | has parent organization: Centers for Disease Control and Prevention | nlx_inv_1005039 | SCR_003958 | 2026-09-12 12:56:06 | 0 | ||||||||||
|
Relypsa Resource Report Resource Website |
Relypsa (RRID:SCR_004047) | RLYP | commercial organization | Biopharmaceutical company focused on development and commercialization of non-absorbed polymeric drugs to treat disorders in areas of renal, cardiovascular and metabolic diseases.February 2021 - Relypsa changed its name to Vifor Pharma. Company is focused on development and commercialization of late stage medicines that will change treatment paradigms and improve patients lives. | biopharmaceutical, pharmaceutical, drug, late stage medicines, late stage medicines commercialization, late stage medicines development | is related to: Kidney Health Initiative | nlx_158475 | SCR_004047 | Relypsa Inc., Vifor Pharma | 2026-09-12 12:56:07 | 0 | ||||||||
|
CADRO Resource Report Resource Website 1+ mentions |
CADRO (RRID:SCR_004046) | CADRO | controlled vocabulary, data or information resource | A classification system developed by the National Institute on Aging and the Alzheimer's Association that can be used to integrate and compare Alzheimer's disease (AD) research portfolios from public and private organizations supporting AD research in the US and abroad. The CADRO was constructed as a three-tier classification system organized around seven major categories: five in research and two resource-related: * Category A. Molecular Pathogenesis and Pathophysiology of Alzheimer's Disease * Category B. Diagnosis, Assessment and Disease Monitoring * Category C. Translational Research and Clinical Interventions * Category D. Epidemiology * Category E. Care, Support and Health Economics of Alzheimer's Diseases * Category F. Research Resources * Category G. Consortia and Public Private Partnerships * Category H. Alzheimer's Disease - Related Dementias Using information from project abstracts and research aims, the above categories were stratified into research topics and these were further divided into research themes. The three levels of classification are meant to enable a fine-grained portfolio analysis that can inform strategic planning and funding decisions. The CADRO was developed as a dynamic portfolio analysis tool that can be used to: (i) capture the changing landscape of AD research funded by different organizations, (ii) identify opportunities for coordination of support for AD research, and (iii) identify funding gaps as well as areas of overlap within and across organizations. | late adult human, alzheimer, aging |
is used by: IADRP has parent organization: Alzheimers Association has parent organization: National Institute on Aging |
Alzheimer's disease, Aging | NIA | nlx_158474 | http://www.nia.nih.gov/research/dn/cadro-outline, http://www.nia.nih.gov/research/dn/common-alzheimers-disease-research-ontology-cadro, http://www.nia.nih.gov/sites/default/files/cadro_outline_-_january_2013.pdf | SCR_004046 | Common Alzheimer''s Disease Research Ontology, Common Alzheimer's Disease Research Ontology (CADRO) | 2026-09-12 12:56:07 | 4 | |||||
|
NIMH Educational Resources Resource Report Resource Website |
NIMH Educational Resources (RRID:SCR_004045) | NIMH Educational Resources | data or information resource, narrative resource, portal, topical portal, training material | A portal to educational resources. | education, mental health, science, human, child, young human |
has parent organization: National Institute of Mental Health is parent organization of: Brain Basics is parent organization of: Neuroscience and Psychiatry Module 1: Translating Neural Circuits into Novel Therapeutics is parent organization of: Science of Mental Illness: Grades 6- 8 is parent organization of: Brain's Inner Workings: Activities for Grades 9 through 12 is parent organization of: Neuroscience and Psychiatry Module 2: Fear/Safety Anxiety and Anxiety Disorders |
NIMH | nlx_146225 | SCR_004045 | National Institute of Mental Health Educational Resources | 2026-09-12 12:56:07 | 0 | |||||||
|
Renal Support Network Resource Report Resource Website 1+ mentions |
Renal Support Network (RRID:SCR_004049) | RSN | data or information resource, disease-related portal, patient-support portal, portal, topical portal | A nonprofit, patient-focused, patient-run organization that provides non-medical services to those affected by chronic kidney disease (CKD). RSN strives to help patients develop their personal coping skills, special talents, and employability by educating and empowering them and their family members to take control of the course and management of the disease. RSN plays a vital role in providing lawmakers and policymakers with the patient''s perspective on the needs and capabilities of people with CKD. | kidney | is related to: Kidney Health Initiative | Chronic kidney disease | nlx_158479 | SCR_004049 | 2026-09-12 12:56:07 | 1 | ||||||||
|
Reata Pharmaceuticals Resource Report Resource Website 1+ mentions |
Reata Pharmaceuticals (RRID:SCR_004040) | Reata | commercial organization | Pharmaceutical company focused on investigating experimental oral antioxidative and anti-inflammatory drugs, which dually activate the antioxidative transcription factor Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) and inhibit the pro-inflammatory transcription factor NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells). The antioxidative and anti-inflammatory compounds bardoxolone methyl and RTA 408 are the lead clinical development compounds in their portfolio. | pharmaceutical, drug, immuno-oncology, ophthalmology, cardiovascular, autoimmune, respiratory, antioxidant inflammation modulator, oxidative stress, medicine, dermatology, skin, eye, clinical trial, nrf2, nf-b, bardoxolone methyl, rta 408, transcription, dna, transcription factor | is related to: Kidney Health Initiative | nlx_158468 | SCR_004040 | Reata Pharmaceuticals Inc. | 2026-09-12 12:56:07 | 2 | ||||||||
|
MSG Resource Report Resource Website 1+ mentions |
MSG (RRID:SCR_004161) | MSG | software resource | A pipeline of scripts to assign ancestry to genomic segments using next-gen sequence data. This method can identify recombination breakpoints in a large number of individuals simultaneously at a resolution sufficient for most mapping purposes, such as quantitative trait locus (QTL) mapping and mapping of induced mutations. | next generation sequencing, genotyping, genetic mapping, ancestry, genome |
is listed by: OMICtools has parent organization: Princeton University; New Jersey; USA |
PMID:21233398 | OMICS_01551 | SCR_004161 | Multiplexed shotgun genotyping, Multiplexed shotgun genotyping (MSG), MSG: Multiplexed Shotgun Genotyping | 2026-09-12 12:56:09 | 2 | |||||||
|
Otsuka America Pharmaceutical Inc. Resource Report Resource Website 1+ mentions |
Otsuka America Pharmaceutical Inc. (RRID:SCR_004036) | OAPI | commercial organization | Healthcare company that oversees all pharmaceutical and medical device commercial activities of Otsuka Group (Otsuka) in North America. Products with emphasis on neuroscience, oncology, cardio-renal, and medical device markets. | pharmaceutical, medical device, neuroscience, oncology, cardio-renal, commercial | is related to: Kidney Health Initiative | nlx_158462 | http://www.otsuka-us.com/Companies/OAPI/ | SCR_004036 | Otsuka America Pharmaceutical | 2026-09-12 12:56:07 | 1 | |||||||
|
Cohorts for Heart and Aging Research in Genomic Epidemiology Resource Report Resource Website 10+ mentions |
Cohorts for Heart and Aging Research in Genomic Epidemiology (RRID:SCR_004034) | CHARGE Consortium, CHARGE | bibliography, consortium, data or information resource, organization portal, portal | Consortium formed to facilitate genome-wide association study meta-analyses and replication opportunities among multiple large and well-phenotyped longitudinal cohort studies. A bibliography of CHARGE publications is available. Its founding member cohorts include: * Age, Gene, Environment, Susceptibility Study -- Reykjavik * Atherosclerosis Risk in Communities Study * Cardiovascular Health Study * Framingham Heart Study * Rotterdam Study Additional core cohorts include: * Coronary Artery Risk Development in Young Adults * Family Heart Study * Health, Aging, and Body Composition Study * Jackson Heart Study * Multi-Ethnic Study of Atherosclerosis | genome-wide association study, genomic, epidemiology, phenotype, longitudinal | is related to: International Genomics of Alzheimers Project | Aging, Heart disease | PMID:20031568 | nlx_158460 | SCR_004034 | 2026-09-12 12:56:07 | 19 | |||||||
|
Proteon Therapeutics Resource Report Resource Website 1+ mentions |
Proteon Therapeutics (RRID:SCR_004037) | Proteon | commercial organization | A biopharmaceutical company developing pharmaceuticals for patients with renal and vascular diseases. Their ongoing Phase 3 clinical trial is evaluating whether a single treatment of PRT-201 can reduce vascular access failure, one of the most serious problems experienced by patients with chronic kidney disease (CKD) undergoing hemodialysis. PRT-201 is an investigational drug that may inhibit neointimal hyperplasia, the growth of tissue inside blood vessels that can result in vessel narrowing and reduced blood flow. PRT-201 has received fast track and orphan drug designations for hemodialysis vascular access indications.In September 2019, Proteon Therapeutics merged with ArTara Therapeutics. | biopharmaceutical, pharmaceutical, hemodialysis, prt-201, drug |
is related to: Kidney Health Initiative is related to: Protara Therapeutics |
Kidney disease, Vascular disease, Chronic kidney disease, Neointimal hyperplasia, Peripheral arterial disease | nlx_158465 | SCR_004037 | Proteon Therapeutics Inc. | 2026-09-12 12:56:07 | 1 | |||||||
|
Brain Tumour Foundation of Canada Resource Report Resource Website |
Brain Tumour Foundation of Canada (RRID:SCR_004158) | Brain Tumour Foundation of Canada | institution | Brain Tumour Foundation of Canada is a dedicated team of volunteers, patients, survivors, family members, health care professionals and staff, determined to make the journey with a brain tumor one full of hope and support. We work collaboratively to serve the needs of those Canadians affected by all types of brain tumors. Information, education and support is available and research continues into the cause of and a cure for brain tumors. Every year, thousands of Canadians affected by brain tumors find emotional support and comfort while gaining a better understanding and knowledge of their disease through a range of programs and services available across the country. This includes: up-to-date brain tumor information material, numerous education events and support groups. Important brain tumor research is also supported through annual grants, a fellowship and the brain tumour tissue bank. We welcome donations, large or small. Charitable Registration #BN118816339RR0001 | brain, tumor, cancer, human | is related to: Lawson Brain Tumour Tissue Bank | individuals ; corporations ; employee groups ; memorial gifts |
ISNI: 0000 0004 5900 0419, nlx_143579, Crossref funder ID: 501100000238, grid.478522.e | https://ror.org/04w23ys68 | SCR_004158 | Brain Tumor Foundation of Canada | 2026-09-12 12:56:09 | 0 | ||||||
|
Multiple Sclerosis Society Resource Report Resource Website 10+ mentions |
Multiple Sclerosis Society (RRID:SCR_004153) | MS Society | nonprofit organization | The UK''s leading MS charity that provides information and support, funding research and fighting for change. We''re a democratic organization: one member, one vote. We fund research, give grants, campaign for change, provide information and support, invest in MS specialists and lend a listening ear to those who need it. The UK''s biggest MS charity. * 38,000 members have a say in how we''re run. * 9000 volunteers give a million hours every year. * 550 staff work in all four nations of the UK. * Over 300 branches support people with MS locally. * One aim: to beat MS. Our national offices in England, Scotland, Wales and Northern Ireland and our network of 300 branches support people affected by MS locally. | Crossref funder ID: 501100000381, ISNI: 0000 0001 0665 6519, nlx_143577, Wikidata: Q6934907, grid.453295.c | https://ror.org/043fwdk81 | SCR_004153 | 2026-09-12 12:56:09 | 18 | ||||||||||
|
Endocells Resource Report Resource Website 10+ mentions |
Endocells (RRID:SCR_004067) | Endocells | commercial organization | This resource no longer in service. Documented on August 12, 2021. French biotech company dedicated to human endocrine cell line production with a first focus on human pancreatic beta cell. Other cell types are being prepared like glucagon cells. The material will be powerful tools for drug discovery, toxicology and cell replacement therapy. Achievements to date * Generated tumoral and non-tumoral human beta cell lines which closely resemble human primary pancreatic beta cells (using technologies which have been first developed and validated using immortalized rat beta cell lines). World first. * Established a robust technology platform which will be used to develop other human endocrine cell lines. | pancreas, endocrine system, replacement cell therapy, glucagon, drug discovery, toxicology, pancreatic beta cell, cell line, human endocrine cell line, beta cell, glucagon cell, tumor |
is listed by: One Mind Biospecimen Bank Listing is related to: IMIDIA |
nlx_158504 | SCR_004067 | Endocells SARL, SARL Endocells | 2026-09-12 12:56:08 | 15 | ||||||||
|
Genomedics Resource Report Resource Website |
Genomedics (RRID:SCR_004103) | Genomedics | commercial organization | A commercial company specialized in the field of clinical governance, research and clinical-epidemiological analysis and development of services and software applications for healthcare. Products and Services * Analysis and development software solutions, web, e-learning * Design and Implementation APP for Smartphone and Tablet (iOS, Android, Windows Phone) * Clinical Intelligence & Clinical Decision Support Systems (CDSS) * Data center services and Application Server Provider * Epidemiology, Surveillance and Health Promotion - Development of studies and epidemiological research | healthcare, clinical, medicine, health, information service, analysis, software development, web portal, multimedia, e-learning, data center service, application server, business intelligence, epidemiology, surveillance, health promotion, population | is related to: EMIF | nlx_158578 | SCR_004103 | Genomedics health care consultants, Genomedics S.r.l. | 2026-09-12 12:56:09 | 0 | ||||||||
|
European ScreeningPort Resource Report Resource Website |
European ScreeningPort (RRID:SCR_004061) | ESP | commercial organization | Commercial organization that aims to bridge the gap between academia and the life-sciences industry with a wide ranging experience in pharmaceutical industry R&D covering multiple target classes and therapeutic areas. This deep scientific insight and established links with world class research institutions is applied across their business groups: * Drug Discovery * Biomarker and Translational Research * Enabling Technologies * R&D Information Technologies They measure their performance by successful outcomes for their collaborators, and recognize that an authentic partnership approach is essential in achieving the goal of converting outstanding science into high quality starting points for new medicines. | pharmaceutical |
is related to: Kinetics for Drug Discovery has parent organization: Mainz Institute of Molecular Biology Bioinformatics Core Facility |
German Federal Ministry of Education and Research ; Norgenta |
nlx_158497 | SCR_004061 | European Screening Port, European Screening Port GmbH, European ScreeningPort GmbH | 2026-09-12 12:56:08 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the Kravitz Resources search. From here you can search through a compilation of resources used by Kravitz and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that Kravitz has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on Kravitz then you can log in from here to get additional features in Kravitz such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into Kravitz you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The data sets included in this resource are published in Kravitz et al, 2012. Distinct roles for direct and indirect pathway striatal neurons in reinforcement (Nat. Neurosci).
